Evidence map›Paper›PMID 40768812›Full record

Trial reportThe Journal of pharmacology and experimental therapeutics2025

Pharmacological study of the safety, efficacy, and potential of M201-A on paroxysmal and persistent atrial fibrillation.

Noboru Kaneko, Godfrey L Smith, Christopher M Loughrey, Ryuko Matsuda, Kengo Kusano, Yuko Inoue, Naoyuki Otani, Masashi Toda, Kayley Scott, Ana Da Silva Costa and 23 more

Abstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Noboru KanekoDepartment of Medicine, Dokkyo Medical University, Tochigi, Japan; AETAS Pharma Co, Ltd, Tokyo, Japan. Electronic address: kanekon@dokkyomed.ac.jp.
Godfrey L SmithSchool of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom. Electronic address: Godfrey.Smith@glasgow.ac.uk.
Christopher M LoughreySchool of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom. Electronic address: Christopher.Loughrey@glasgow.ac.uk.
Ryuko MatsudaAETAS Pharma Co, Ltd, Tokyo, Japan; Nojima Hospital, Tottori, Japan.
Kengo KusanoDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Centre, Osaka, Japan.
Yuko InoueDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Centre, Osaka, Japan.
Naoyuki OtaniDokkyo Medical University Nikko Medical Center, Tochigi, Japan.
Masashi TodaAETAS Pharma Co, Ltd, Tokyo, Japan.
Kayley ScottSchool of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.
Ana Da Silva CostaSchool of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.
Sara DobiSchool of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.
Priyanka SaxenaSchool of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.
Patrick B MarkSchool of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.
Makoto ShinozakiAETAS Pharma Co, Ltd, Tokyo, Japan.
Ryuichi KambayashiDepartment of Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan.
Alexandra RiddellSchool of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.
Elspeth B ElliottSchool of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.
Charlotte S McCarrollSchool of Cardiovascular and Metabolic Health, University of Glasgow, University Place, Glasgow, United Kingdom.
Takeshi KitaiDepartment of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan.
Tomoko HasunumaClinical Trial Center, Kitasato University Kitasato Institute Hospital, Kanagawa Japan.
Ken ShimamotoSendai Cardiovascular Center, Miyagi, Japan.
Toshiya SakaiAETAS Pharma Co, Ltd, Tokyo, Japan.
Masahiko NakamuraTomoni Kangaeru Clinic Honjo Waseda, Saitama, Japan.
Migaku KikuchiDepartment of Cardiovascular Medicine, Dokkyo Medical University, Tochigi, Japan.
Shigeru ToyodaDepartment of Cardiovascular Medicine, Dokkyo Medical University, Tochigi, Japan.
Tetsuya IshikawaDepartment of Cardiology, Dokkyo Medical University, Saitama Medical Center, Saitama, Japan.
Koichiro KumagaiHeart Rhythm Center, Fukuoka Sanno Hospital, Fukuoka, Japan.
Isao TaguchiDepartment of Cardiology, Dokkyo Medical University, Saitama Medical Center, Saitama, Japan.
Atsushi SugiyamaDepartment of Pharmacology, Faculty of Medicine, Toho University, Tokyo, Japan.
Yasuki KiharaKobe City Medical Center General Hospital, Kobe, Japan.
Toshihiko FujiwaraAETAS Pharma Co, Ltd, Tokyo, Japan.
Yuji KumagaiKitasato University, Minato-ku, Tokyo, Japan.
Kunio IwataAETAS Pharma Co, Ltd, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conversion and prevention of atrial fibrillation (AF) are essential requirements for its treatment. Abnormal leakage of calcium from the sarcoplasmic reticulum via the ryanodine receptor 2 (RyR2) during diastole is considered a major cause of AF. Although catheter ablation has made it possible to stop persistent AF, it does not address recurrence. In this context, we describe the additional pharmacological and antiarrhythmic effects of the RyR2 inhibitor M201-A, including the results of a phase I study. M201-A inhibited G-protein-gated atrial K

Indexed as

Anti-Arrhythmia AgentsAtrial FibrillationAction PotentialsAdultAgedAnimalsDouble-Blind MethodFemaleHumansMaleMiddle AgedMyocytes, CardiacRabbitsRyanodine Receptor Calcium Release ChannelThiazepinesTreatment OutcomeAnti-Arrhythmia AgentsK201 compoundRyanodine Receptor Calcium Release ChannelThiazepinesCatheter ablationFridericia's corrected QT intervalParoxysmal atrial fibrillationPersistent atrial fibrillationRyR2Torsades de pointes

Identifiers

PMID40768812
PMCPMC12489371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.